Express Pharma

Biocon Biologics completes integration of Viatris Biosimilars’ Business in North America

With the completion of the North America integration, the existing commercialised portfolio of biosimilars, Ogiviri (bTrastuzumab), Fulphila (bPegfilgrastim), Semglee (Insulin Glargine) and Hulio* (bAdalimumab), is now incorporated into Biocon Biologics’ commercial organisation